Enzo Biochem (NYSE:ENZ) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report issued on Sunday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of Enzo Biochem stock opened at $0.48 on Friday. Enzo Biochem has a fifty-two week low of $0.41 and a fifty-two week high of $1.30. The company’s 50 day moving average price is $0.55 and its two-hundred day moving average price is $0.86.

Enzo Biochem (NYSE:ENZ) last issued its earnings results on Monday, March 17th. The medical research company reported ($0.02) earnings per share for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%. The company had revenue of $7.33 million during the quarter.

Institutional Trading of Enzo Biochem

A number of hedge funds have recently added to or reduced their stakes in the stock. Mink Brook Asset Management LLC acquired a new stake in Enzo Biochem in the fourth quarter valued at approximately $577,000. Geode Capital Management LLC lifted its holdings in shares of Enzo Biochem by 3.3% during the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after purchasing an additional 11,742 shares during the period. Wittenberg Investment Management Inc. lifted its holdings in shares of Enzo Biochem by 60.1% during the fourth quarter. Wittenberg Investment Management Inc. now owns 187,537 shares of the medical research company’s stock worth $134,000 after purchasing an additional 70,400 shares during the period. Lepercq Multi Asset Fund acquired a new position in shares of Enzo Biochem during the fourth quarter worth $88,000. Finally, BBR Partners LLC acquired a new position in shares of Enzo Biochem during the third quarter worth $112,000. Institutional investors and hedge funds own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.